METTL14‐mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Zhuonan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, First Hospital of China Medical University, Shenyang City, Liaoning Province, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, STAT3 Transcription Factor, Methyltransferases, Kidney Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Doctoral Research Initiation Fund of the Joint Fund Program of Liaoning province, Liaoning Provincial Science Program Foundation.
Abstract (Originalsprache)
Therapeutic options for advanced clear cell renal cell carcinoma (ccRCC) are currently inadequate. Earlier research has shown that the enzyme methyltransferase‐like 14 (METTL14) can suppress ccRCC development through the modification of N6‐methyladenosine (m6A). This study further explored its complex biological functions and underlying molecular mechanisms. Here, we identified zinc finger protein 14 (ZFP14) as a novel target of METTL14‐mediated m6A, and its under‐expression was associated with ccRCC tumourigenesis and progression. Detailed investigations revealed that METTL14 interacted directly with the 3′ untranslated region of ZFP14 mRNA, promoting m6A modification at two specific sites. These modifications were recognised by the protein insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2), which stabilised and enhanced the expression of ZFP14 mRNA. Functionally, the METTL14/ZFP14 axis suppressed in vitro growth, migration and invasiveness and in vivo proliferation and metastasis of ccRCC cells. ZFP14 potentially regulated numbers of transcripts, among which matrix metalloproteinase 1/3 (MMP1/3) were validated to be under‐expressed by ZFP14. Crucially, ZFP14 interacted with the signal transducer and activator of transcription 3 (STAT3), augmenting its K48‐linked ubiquitination and destabilising it via the proteasome pathway. Moreover, ZFP14 repressed ccRCC cell in vivo growth and metastasis as well as decreasing MMP1/3 levels by under‐expressing STAT3. These observations confirmed that ZFP14 served as both a novel target for METTL14‐mediated m6A modification and a significant tumour suppressor in ccRCC, shedding light on the cellular and molecular operations in ccRCC and opening up possibilities for novel therapeutic strategies. Key points ZFP14 under‐expression is associated with ccRCC tumourigenesis and progression. METTL14‐mediated m6A enhances ZFP14 mRNA stability and expression with IGF2BP2 as the reader in ccRCC. ZFP14 promotes the degradation of STAT3 by enhancing its K48‐linked ubiquitination, inhibiting ccRCC progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, First Hospital of China Medical University, Shenyang City, Liaoning Province, China.
- Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
ORCID-Profile: Chiyuan Piao, Xiaotong Zhang
Förderung
- National Natural Science Foundation of China
- Doctoral Research Initiation Fund of the Joint Fund Program of Liaoning province
- Liaoning Provincial Science Program Foundation
Zitieren
APA
Liu, Z., Sun, T., Zhang, Z., Piao, C., Kong, C., & Zhang, X. (2025). METTL14‐mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70232
Vancouver
Liu Z, Sun T, Zhang Z, Piao C, Kong C, Zhang X. METTL14‐mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70232
BibTeX
@article{Liu2025,
author = {Liu, Zhuonan and Sun, Tianshui and Zhang, Zhe and Piao, Chiyuan and Kong, Chuize and Zhang, Xiaotong},
title = {METTL14‐mediated m6A modification of ZFP14 inhibits clear cell renal cell carcinoma progression via promoting STAT3 ubiquitination},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70232}
}
EUVIMED